Welcome to our dedicated page for Provectus Biopha news (Ticker: PVCT), a resource for investors and traders seeking the latest updates and insights on Provectus Biopha stock.
Provectus Biopharmaceuticals, Inc. (PVCT) is a clinical-stage biotechnology company whose news flow centers on the development of immunotherapy medicines based on halogenated xanthenes, particularly its lead molecule rose bengal sodium. As an OTCQB-traded company, Provectus regularly issues updates on preclinical and clinical research, investor events, and corporate initiatives that shape the outlook for its investigational programs.
News about Provectus often highlights progress with PV-10, the company’s rose bengal sodium-based investigational cancer immunotherapy. Recent announcements have covered preclinical studies in head and neck squamous cell carcinoma, orthotopic bladder cancer models using oral and intravesical PV-10, and mechanistic work showing activation of the STING immune pathway and enhanced T-cell responses in vaccine settings. These items provide insight into how the company is exploring PV-10 across oncology and immunology applications.
Investors and researchers following PVCT can also expect updates on wound healing and dermatology research, such as non-clinical data on full-thickness cutaneous wounds, as well as ophthalmology developments through the VisiRose founded entity focused on rose bengal sodium-based eye therapies. Additional news items include announcements of annual stockholder meetings, investor webinars, and conference calls, which offer company updates and access to management presentations.
This PVCT news page aggregates these disclosures in one place, making it easier to review Provectus’s latest scientific publications, collaboration highlights, and corporate communications. For anyone tracking the evolution of its rose bengal sodium platform across oncology, dermatology, ophthalmology, infectious diseases, and tissue repair research, this feed provides an organized view of the company’s reported milestones and ongoing activities.
Provectus (PVCT) announced an expansion of its sponsored research program with Dr. Aru Narendran at the University of Calgary, focusing on the treatment of pediatric leukemia using its proprietary rose bengal. The research aims to identify effective drug combinations, evaluate drug administration routes, and explore the modulation of specific pathways. Previous studies have shown promising in vitro activity of rose bengal against leukemia cells and initial in vivo effectiveness in mouse models.
Provectus (OTCQB: PVCT) has launched a new sponsored research program with Dr. Kelly Tseng from the University of Nevada, Las Vegas, aimed at studying the effects of rose bengal sodium (RBS) on vertebrate tissue regeneration. The research will utilize the African clawed frog as a model organism to evaluate key biological processes such as embryo development and wound healing. RBS is Provectus' lead compound in a class of small molecules known as halogenated xanthenes, which the company exclusively owns.
Provectus (OTCQB: PVCT) announced updated data from its Phase 1 trial targeting metastatic uveal melanoma (mUM) patients treated with the investigational immunocatalyst PV-10. Presented at the 20th Congress of the International Society of Ocular Oncology in June 2022, findings highlighted successful responses in patients receiving PV-10 injections. The study allows for multiple tumor injections per treatment cycle with assessments every three months. Provectus continues to develop various immunotherapy medicines, focusing on oncology and other disease areas.
Provectus (OTCQB: PVCT) announced on June 23, 2022, that shareholders approved a reverse stock split and an authorized share reduction during the 2022 Annual Meeting held on June 22. Other approved proposals include the election of directors and executive compensation. The Board aims to enhance shareholder value through these measures. Detailed voting results are available in Provectus' Form 8-K filed the same day. The company focuses on developing immunotherapy medicines for various diseases, particularly in oncology and dermatology.
Provectus (PVCT) announced promising results from its Phase 1 trial of PV-10 for metastatic uveal melanoma (mUM), presented at ASCO 2022. Notably, 29% of Stage IV M1a mUM patients achieved a metabolic complete response (mCR), with survival times ranging from 12.4 to over 48.8 months post-treatment. The trial utilized advanced imaging techniques like PET-CT, affirming their effectiveness in monitoring treatment response. The findings suggest that PV-10 combined with immune checkpoint blockade may enhance patient outcomes, emphasizing the need for early intervention in mUM.
Provectus (OTCQB: PVCT) announced that the USPTO has allowed its patent application 16/204,832 for a combination of topical PH-10 and systemic therapies to treat inflammatory skin conditions, including psoriasis and atopic dermatitis. This marks Provectus’ first patent award in dermatology. The patent is co-assigned with Rockefeller University, with Dr. James Krueger as co-inventor. PH-10 is a clinical-stage immunotherapy treatment. The company focuses on developing halogenated xanthene-based therapies across various medical areas, including oncology and virology.
Provectus (OTCQB: PVCT) announced that data from its ongoing clinical trial of PV-10, an investigational cancer immunotherapy, will be presented at the ASCO 2022 annual meeting from June 3-7, 2022, in Chicago. The focus is on treating metastatic uveal melanoma (mUM) to the liver. Key details include:
- Abstract Title: Metabolic complete responses in mUM patients treated with PV-10
- Abstract Number: 9543
- Session Date: June 6, 2022, 1:15-4:15 PM CDT
This presentation highlights the potential of PV-10 in oncology.
Provectus (OTCQB: PVCT) announced that the USPTO has allowed patent application 16/688,319, which covers the use of PV-10 for treating hematologic cancers. This marks Provectus' first patent award in hematology. In vivo studies showed that mice with acute lymphoblastic leukemia treated with oral PV-10 had increased survival rates compared to control groups. Innovate Calgary is a co-assignee for this patent, with a co-inventor from the University of Calgary.
KNOXVILLE, TN, April 19, 2022 – Provectus (OTCQB: PVCT) announced proposals for its 2022 Annual Meeting on June 22, including a reverse stock split ranging from 1-for-10 to 1-for-50 and a corresponding authorized share reduction. Approval for these measures is contingent upon the reverse stock split passing. Other items on the agenda include director elections, executive compensation approval, and ratification of the independent accounting firm. A definitive proxy statement will follow the preliminary filing pending SEC review.
Provectus announced the addition of Dr. Aru Narendran to its Scientific Advisory Board. Dr. Narendran, a professor at the University of Calgary, is recognized for his significant contributions to pediatric oncology. His collaboration with Provectus over the past five years has led to preclinical research on the drug rose bengal sodium (RBS), which shows promise in treating various cancers including neuroblastoma and acute leukemias. The partnership has also resulted in multiple patents and unique discoveries related to RBS. Provectus values Dr. Narendran's insights to enhance its drug development efforts.